Incyte | INCY - 流动负债



金融业
股票价格
USD
资产
USD 7.34B
现金及等价物
USD 4.02B
销售成本
USD 104.5M
流动资产
USD 5.48B
流动负债
USD 1.49B
债务
USD 39.43M
EBIT
USD 344.17M
EBITDA
USD 367.97M
员工
2.62K
EPS每股收益
USD 1.81
股本和储备
USD 5.62B
销售毛利
USD 1.17B
债务利息支出
USD 569K
利息收入
USD 33.69M
贷款资金
USD 29.41M
市值
USD 21.82B
净收入
USD 303.33M
营业费用
USD 5.62B
营业利润
USD 324.17M
普通股股本
USD 199.95M
PE价格收益
15.35
税前利润
USD 343.6M
销售收入
USD 1.27B
销售和管理费用
USD 328.1M
股票
USD 115.62M
贸易债权人
USD 228.62M
应收帐款人
USD 1.05B


流动负债 更改 日
Acadia Pharmaceuticals USD 305.52M 28.41M 2026-03
Agenus USD 249.24M 74.25M 2026-03
Agios Pharmaceuticals USD 58.84M 23.36M 2026-03
Alnylam Pharmaceuticals USD 1.35B 116.87M 2026-03
Amgen USD 24.96B 534M 2026-03
BioCryst Pharmaceuticals USD 195.39M 675K 2026-03
Biogen USD 3B 350.5M 2026-03
BioMarin Pharmaceutical USD 793.15M 34.12M 2026-03
Bristol-Myers Squibb USD 19.16B 4.26B 2026-03
Eli Lilly USD 36.63B 1.41B 2026-03
Exelixis USD 370.98M 34.67M 2026-03
Gilead Sciences USD 9.48B 2.34B 2026-03
Incyte USD 1.49B 25.52M 2026-03
Ionis Pharmaceuticals USD 717M 66M 2026-03
MacroGenics USD 95.94M 52.82M 2026-03
Merck USD 26.94B 1.38B 2026-03
Moderna USD 2.4B 408M 2026-03
Nektar Therapeutics USD 53.54M 12.8M 2025-12
Neurocrine Biosciences USD 831.7M 88.3M 2026-03
Novartis USD 31.37B 4.1B 2026-03
Novartis USD 27.28B 4.72B 2025-12
Pfizer USD 34.35B 2.64B 2026-03
PTC Therapeutics USD 923.6M 44.82M 2026-03
Puma Biotechnology USD 82.73M 3.63M 2025-09
Regeneron Pharmaceuticals USD 5.11B 739.3M 2026-03
Sarepta Therapeutics USD 499.16M 596.13M 2026-03
Ultragenyx Pharmaceutical USD 325M 59M 2026-03
Vertex Pharmaceuticals USD 3.88B 19.4M 2026-03